Soleno Therapeutics (SLNO) Asset Utilization Ratio (2015 - 2026)

Soleno Therapeutics (SLNO) reported Asset Utilization Ratio of 0.49 for Q1 2026, up 48.6% quarter-over-quarter from 0.33 in Q4 2025.

Soleno Therapeutics (SLNO) Asset Utilization Ratio (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 5 years of Asset Utilization Ratio data on file, last reported at 0.49 in Q1 2026.

Asset Utilization Ratio for Q1 2026 came in at 0.49, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.49 (changed N/A YoY), and the FY2025 annual result was 0.43, changed N/A from the prior year.
Asset Utilization Ratio rose to 0.49 in Q1 2026 per SLNO's latest filing, from 0.33 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.49 in Q1 2026 and troughed at 0.11 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	0.55
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.60
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	1,422.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.47
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Soleno Therapeutics	2.76 Bn	2.51 Bn	93.41 Mn	0.49

Download Data